AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30580905 — intervention group
Group type: COMPARATOR
Intervention: Standard information materials (Control)
Number of subjects: 82
Study 27298379 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12±1.67 mg/day)
Number of subjects: 140
Study 27298379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 27298379 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 140
Study 25953480 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylamide hydrogel filler
Number of subjects: 31
Study 24192420 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive-controlling 3D webpages (P3)
Number of subjects: 0
Study 24192420 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-controlling 3D webpages (A3)
Number of subjects: 0
Study 24192420 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2D webpages (2D)
Number of subjects: 0
Study 22094037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (4 g/L)
Number of subjects: 90
Study 22094037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine plus Phenylephrine (ephedrine 2 g/L + phenylephrine 25 mg/L)
Number of subjects: 90
Study 22094037 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (50 mg/L)
Number of subjects: 90
Study 19131811 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient model (group II)
Number of subjects: 70
Study 19131811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical model (group III)
Number of subjects: 70
Study 19131811 — intervention group
Group type: COMPARATOR
Intervention: Neither model (group I)
Number of subjects: 70
Study 21606948 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (standard FDA-approved regimen)
Number of subjects: 397
Study 16191054 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive continuous monitoring method (NICOMM) using laser-Doppler flowmeter (LDF) at 780 nm
Number of subjects: 0
Study 16191054 — intervention group
Group type: COMPARATOR
Intervention: Continuous hematocrit monitor (Crit-Line monitor, CLM)
Number of subjects: 0
Study 12779280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream (6%)
Number of subjects: 0
Study 12779280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine cream (4%)
Number of subjects: 0
Study 10684018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.82 g.kg‐1.d‐1 fat emulsion (42% of total calorie)
Number of subjects: 20
Study 10684018 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.72 g.kg‐1.d‐1 fat emulsion (52% of total calorie)
Number of subjects: 20
Study 7936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 442
Study 7936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 442
Study 7936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogens
Number of subjects: 442
Study 7936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-calcium
Number of subjects: 442
Study 7936382 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 442
Study 2672426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Number of subjects: 91
Study 2672426 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 322634 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-arousing, gestalt therapy
Number of subjects: 33
Study 322634 — intervention group
Group type: COMPARATOR
Intervention: Meditation-Tai Chi (Control)
Number of subjects: 33
Study 29775202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 μM with 0.05% DMSO
Number of subjects: 13
Study 29775202 — intervention group
Group type: COMPARATOR
Intervention: 0.05% DMSO without aspirin
Number of subjects: 13
Study 26024743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 6 mg once per cycle
Number of subjects: 306
Study 26024743 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim 6 mg once per cycle
Number of subjects: 306
Study 25675651 — intervention group
Group type: EXPERIMENTAL
Intervention: PB U-MDT
Number of subjects: 342
Study 25675651 — intervention group
Group type: COMPARATOR
Intervention: PB R-MDT
Number of subjects: 342
Study 22638902 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy MOMs Healthy Lifestyle Intervention (MOMs)
Number of subjects: 275
Study 22638902 — intervention group
Group type: COMPARATOR
Intervention: Healthy Pregnancy Education (control)
Number of subjects: 275
Study 20105189 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4410646 genotype (CC)
Number of subjects: 981
Study 20105189 — intervention group
Group type: COMPARATOR
Intervention: rs4410646 genotype (AC and AA)
Number of subjects: 981
Study 20105189 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7703713 genotype (GA and AA)
Number of subjects: 981
Study 20105189 — intervention group
Group type: COMPARATOR
Intervention: rs7703713 genotype (not specified)
Number of subjects: 981
Study 19038898 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 478
Study 19038898 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic comparison subjects
Number of subjects: 478
Study 15972580 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/d ED-71
Number of subjects: 219
Study 15972580 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 microg/d ED-71
Number of subjects: 219
Study 15972580 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/d ED-71
Number of subjects: 219
Study 15972580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 12814996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (>/=25 cigarettes/day)
Number of subjects: 68
Study 12814996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking (>/=5 drinks/day)
Number of subjects: 68
Study 12814996 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable consumption (highest level)
Number of subjects: 68
Study 12814996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit consumption (highest level)
Number of subjects: 68
Study 12814996 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil consumption (highest level)
Number of subjects: 68
Study 10570387 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% tetracaine cream
Number of subjects: 72
Study 10570387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8556225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily for 12 weeks
Number of subjects: 11
Study 8556225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1816827 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective measures of oral hygiene (monthly, quarterly, half-yearly intervals)
Number of subjects: 442
Study 1816827 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice instructed measures of oral hygiene
Number of subjects: 442
Study 7280450 — intervention group
Group type: EXPERIMENTAL
Intervention: Octavalent vaccine (Eli Lilly Laboratories) given at six months and/or 12 months of age
Number of subjects: 0
Study 7280450 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent vaccine (Merck Sharp & Dohme) given at 12 months of age
Number of subjects: 0
Study 7280450 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 0
Study 7280450 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including controls) by age 24 months
Number of subjects: 0
Study 7280450 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reactions post-vaccination
Number of subjects: 0
Study 30712247 — intervention group
Group type: EXPERIMENTAL
Intervention: VKORC1 genetic evaluation
Number of subjects: 127
Study 30712247 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosing based on genetic testing
Number of subjects: 127
Study 28844878 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 8 using the modified EvoInserter®
Number of subjects: 965
Study 27363396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to (n=16)
Number of subjects: 58
Study 27363396 — intervention group
Group type: COMPARATOR
Intervention: Eperisone hydrochloride (n=14)
Number of subjects: 58
Study 27363396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to (2.5 g as needed)
Number of subjects: 58
Study 27363396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to (7.5 g/day)
Number of subjects: 58
Study 27363396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to
Number of subjects: 58
Study 24118416 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention trial to improve symptoms and quality of life
Number of subjects: 143
Study 24118416 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy (n = 73)
Number of subjects: 143
Study 21251805 — intervention group
Group type: COMPARATOR
Intervention: Nasal LTB4
Number of subjects: 61
Study 19878793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) using RX Acculink stent and RX Accunet embolic protection system
Number of subjects: 2522
Study 19878793 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2522
Study 19878793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2522
Study 19878793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) and Carotid endarterectomy (CEA)
Number of subjects: 2522
Study 17761981 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (two schedules)
Number of subjects: 1006
Study 17761981 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone with prednisone
Number of subjects: 1006
Study 15227690 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum (CLC)
Number of subjects: 50
Study 15227690 — intervention group
Group type: COMPARATOR
Intervention: Gasless laparoscopic cholecystectomy (GLC)
Number of subjects: 50
Study 10834424 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE901 (0.4 U/kg body wt)
Number of subjects: 15
Study 10834424 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 15
Study 10834424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9138853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (hydrophilic beta-blocker)
Number of subjects: 20
Study 9138853 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (lipophilic beta-blocker)
Number of subjects: 20
Study 9138853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9138853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 20
Study 9138853 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 7681516 — intervention group
Group type: COMPARATOR
Intervention: Oral dofetilide (5 micrograms/kg)
Number of subjects: 18
Study 7681516 — intervention group
Group type: COMPARATOR
Intervention: Oral dofetilide (7.5 micrograms/kg)
Number of subjects: 18
Study 7681516 — intervention group
Group type: COMPARATOR
Intervention: Oral dofetilide (10 micrograms/kg)
Number of subjects: 18
Study 7681516 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dofetilide (0.5 mg)
Number of subjects: 18
Study 7681516 — intervention group
Group type: COMPARATOR
Intervention: Oral dofetilide (0.5 mg)
Number of subjects: 18
Study 2877594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg/kg)
Number of subjects: 0
Study 2877594 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 0
Study 2877594 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% and 0.1 mg fentanyl (control group C)
Number of subjects: 0
Study 2877594 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 0
Study 29660297 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated family planning curriculum (intervention school)
Number of subjects: 217
Study 29660297 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical curriculum (control schools)
Number of subjects: 217
Study 27686403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CAF solution
Number of subjects: 8
Study 27686403 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 8
Study 27686403 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no prior glycogen depletion)
Number of subjects: 8
Study 23937927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact anterior supraspinatus tendon (Group 1)
Number of subjects: 112
Study 23937927 — intervention group
Group type: COMPARATOR
Intervention: Disrupted anterior supraspinatus tendon (Group 2)
Number of subjects: 112
Study 22969732 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg plus d-amphetamine 30 mg
Number of subjects: 73
Study 22969732 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 60 mg
Number of subjects: 73
Study 22969732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 22969732 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 73
Study 20636552 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation with dry, room temperature carbon dioxide for 2 minutes
Number of subjects: 10
Study 19112722 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg per day
Number of subjects: 18
Study 19112722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg per day
Number of subjects: 18
Study 19112722 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Acetylsalicylic acid and Ibuprofen)
Number of subjects: 18
Study 15996057 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 201
Study 12427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiver of consent used in 62% of patients enrolled during the trial period.
Number of subjects: 392
Study 12427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from injury to randomization in the first 9 months was 4.5 ± 1.2 h; time to target temperature was 11.7 ± 2.6 h.
Number of subjects: 392
Study 12427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiver of consent usage among different demographics: 53% of minorities, 47% of unskilled workers, 33% of nonminorities, and 29% of skilled or professional workers.
Number of subjects: 392
Study 10209373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline
Number of subjects: 60
Study 10209373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 3% with felypressin 0.03 IU.ml‐1
Number of subjects: 60
Study 10209373 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine and 0.5% bupivacaine
Number of subjects: 60
Study 10209373 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 60
Study 7562650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic elastic response feet (DER)
Number of subjects: 17
Study 7562650 — intervention group
Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 17
Study 7562650 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic amputees
Number of subjects: 17
Study 7562650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysvascular amputees
Number of subjects: 17
Study 2204995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 24
Study 385822 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried cortical powdered allografts of bone
Number of subjects: 9
Study 385822 — intervention group
Group type: COMPARATOR
Intervention: Flap and curettage control
Number of subjects: 9
Study 385822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongrafting procedures
Number of subjects: 9
Study 30565096 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC)
Number of subjects: 158
Study 30565096 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide (20 or 40 mg with 300 mg SNAC)
Number of subjects: 158
Study 30565096 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide (40 mg with 300 mg SNAC)
Number of subjects: 158
Study 30565096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 158
Study 29494545 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-Cycled Operation (TCO) using a single commercial MOS gas sensor
Number of subjects: 0
Study 27509601 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming-needle moxibustion
Number of subjects: 61
Study 27509601 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 61
Study 25311998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Intervention Strategy (CIS) including point-of-care CD4 count testing, accelerated antiretroviral therapy initiation, SMS reminders for linkage and retention in care
Number of subjects: 2250
Study 25311998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Intervention Strategy plus Financial Incentives (CIS + FI)
Number of subjects: 2250
Study 25311998 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 2250
Study 22791228 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (10 min, 1 mA)
Number of subjects: 6
Study 22791228 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 20837352 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of test oil containing 27.3% DAG
Number of subjects: 22
Study 20837352 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of test oil containing 54.6% DAG
Number of subjects: 22
Study 20837352 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 22
Study 16358297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0
Study 16358297 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study 16325031 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg/day for 10 days starting 2 days before repeat intervention)
Number of subjects: 180
Study 16325031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16325031 — intervention group
Group type: COMPARATOR
Intervention: Imatinib and Placebo
Number of subjects: 180
Study 11849868 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity bicycle exercise (45 minutes at 50% maximal oxygen uptake)
Number of subjects: 24
Study 11849868 — intervention group
Group type: COMPARATOR
Intervention: Rest (45 minutes)
Number of subjects: 24
Study 9667294 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ketamine infiltration
Number of subjects: 15
Study 9667294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9667294 — intervention group
Group type: COMPARATOR
Intervention: Systemic ketamine
Number of subjects: 15
Study 7906539 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 75
Study 7906539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 4%
Number of subjects: 75
Study 7906539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Apraclonidine 1% and Pilocarpine 4%)
Number of subjects: 75
Study 2780105 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/24 h for 7 days plus saline irrigation of the operative site.
Number of subjects: 171
Study 2780105 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam (2 g intraoperatively, 2 g at 12 hours and 24 hours post-surgery) plus Povidone iodine (5% dilution) irrigation of the operative site.
Number of subjects: 171
Study 1219635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (600 to 800 mg)
Number of subjects: 33
Study 1219635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1219635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 33
Study 6985706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times a day)
Number of subjects: 1558
Study 6985706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 31194885 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg and 30 mg extended-release once daily)
Number of subjects: 574
Study 31194885 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (twice-daily dosing of immediate-release formulation)
Number of subjects: 574
Study 31194885 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (extended-release)
Number of subjects: 574
Study 29493811 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing rent subsidy plus intensive case management (ICM)
Number of subjects: 0
Study 29493811 — intervention group
Group type: COMPARATOR
Intervention: Intensive case management (ICM) alone
Number of subjects: 0
Study 29493811 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing rent subsidy
Number of subjects: 0
Study 29871185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic injection with mouse nerve growth factor and methylprednisolone
Number of subjects: 149
Study 29871185 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication and methylprednisolone (0.5 ml) + 0.9% NaCl (0.5 ml)
Number of subjects: 149
Study 24589090 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (oral supplementation containing arginine, ω‐3 fatty acids, and RNA for 5 days before surgery)
Number of subjects: 50
Study 24589090 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 50
Study 24589090 — intervention group
Group type: COMPARATOR
Intervention: Control (no artificial nutrition, regular food allowed before surgery)
Number of subjects: 50
Study 24589090 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 22302817 — intervention group
Group type: EXPERIMENTAL
Intervention: Funny stimuli
Number of subjects: 15
Study 22302817 — intervention group
Group type: COMPARATOR
Intervention: Positive stimuli
Number of subjects: 15
Study 22302817 — intervention group
Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 15
Study 22302817 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 15
Study 20817383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (parent-delivered intervention + BASICS)
Number of subjects: 1275